Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 2/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30823280 | 1.00 | L3MBTL1 (0.38) | L3MBTL1ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL21187335 | 1.00 | L3MBTL1 (0.38) | L3MBTL1ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL21177900 | 0.83 | DCLK1 (0.39) | L3MBTL1ALDH1A1MAPK1SYK | |
| SCHEMBL21187336 | 0.83 | DCLK1 (0.39) | L3MBTL1ALDH1A1MAPK1SYK | |
| SCHEMBL30823307 | 0.83 | DCLK1 (0.39) | L3MBTL1ALDH1A1MAPK1SYK | |
| SCHEMBL16040372 | 0.79 | ALDH1A1 (0.37) | L3MBTL1ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL30790686 | 0.79 | ALDH1A1 (0.37) | L3MBTL1ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL30790682 | 0.79 | ALDH1A1 (0.37) | L3MBTL1ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL16039398 | 0.79 | ALDH1A1 (0.37) | L3MBTL1ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL21187303 | 0.75 | L3MBTL1 (0.34) | L3MBTL1ADRA1DADRA1AADRA1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12005127-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-11 | — | — | US | disclosed |
| CN-111757876-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3740480-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-3740480-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| CN-111757876-A | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | L3MBTL1 2056/4885ADRA1D 3777/4885ADRA1A 3666/4885 |
| US-12005127-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | L3MBTL1 2056/4885ADRA1D 3777/4885ADRA1A 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.